



## What's Hot

**ACW** - Actinogen Medical Limited today closed up 6% to finish at 4.7c on \$2.1m stock traded. The reason they are up today is because they had two major announcements that did see the stock trade as high as 5.3c intra day but drifted back going into the close.

I do have clients that hold this stock and believe it or not - I know it sounds like I am talking sh\*t but I am not.

I met up with the CEO and MD recently Dr Bill Ketelby and I was impressed with what I heard and I did buy a few for clients after our meeting so today's new was very pleasing to see.

The first bit of news today was that it has completed its Interim Analysis on the first 50 evaluable patients in its XanADu clinical trial. This study saw early safety and efficacy data reviewed by the independent Data and Safety Monitoring Board (DSMB) that concluded that the trial should continue without modification.

No adverse events were reported and the DSMB confirmed that the positive benefit-risk safety profile of the drug supports the expectation that the study is progressing as planned. So essentially, everything is going according to plan.

The Company said it continues to enroll patients into the trial, with a total of 100 patients to date. Enrolment of the total 174 patients is expected to complete in Q4 CY18, with top line results available by Q2 CY19. So, less than a year from now!

The Company also announced today a capital raise of \$15m and which boasts a cornerstone US biotech investor, Biotechnology Value Fund L.P (BVF) who will invest \$10.5m and end up with a 19.9% holding.

The Placement was done at a 13.4% premium to the 5-day VWAP, showing the market the value being placed on the business by a big biotech investor. (mkt seems to like a premium or at the money raise at the moment that's for sure)

Other leading Australian institutional investors, including Platinum Asset Management and Australian Ethical will also come onto the register via the Placement.

The raise was done by the boys and girls at Bell Potter, so well done to them and thanks for getting my paper work done today also just FYI !!!

Actinogen will also undertake an SPP to raise a further \$2m to allow all its lucky existing shareholders to increase their holdings.

The SPP will bring the total capital raised to \$17m, leaving the Company well-funded to advance the development of its Xanamem drug for the treatment of Alzheimer's disease and into other indications that will expand the market opportunity and open up further potential partnerships and discussions.

Alzheimer's disease is a prevalent and devastating disease that has recently become the leading cause of death for Australian women. It is about time a new and novel treatment comes to market and Actinogen could do just that.

This is certainly a biotech to watch as some of you would remember I wrote about them in detail a few weeks or maybe months ago and I won't share today's news below as this report is long enough and if you are really that interested in the stock ..... you know what to do !!!

**Get Long Stay Strong**

Nick Kelso

Client Adviser

p: 02 8379 2962

m: 0404 003 613

e: [nk@huntercap.com.au](mailto:nk@huntercap.com.au)

For Hunter Capital Advisors Pty Ltd Disclaimer click [here](#)

For a free subscription to the full report please email Nick Kelso



The idea of this report is to be informative and hopefully point out stocks that you wouldn't ordinarily have seen during the day.

This report IS NOT personal advice.

**It is very important to refer to the ASX website for information on any stocks that are contained in this report and as always please consult your financial adviser before acting .**

This report is written by myself and the views in this report may not accurately reflect the same views as Hunter Capital.

If I have bought stocks or hold them I will let you know about it but it doesn't mean that it is a good buy.

If looking at anything mentioned in this report **please consult your financial adviser before acting.**

This report is written by myself, I don't have the luxury of having a big team to help with this report there will be errors in this report, spelling mistakes, grammar mistakes, closing prices etc etc.

Please check all the facts yourself and don't take what I have written quickly between 4pm & 6pm as gospel.

If you are a broker or even investor that is receiving this report more than happy to get ideas and feedback on stocks that you think I should be looking at or writing about.

**I will not tolerate any keyboard warriors.**

' The trend is your friend ..... until the bend at the end'

If you don't like what I write or my writing style please just email me unsubscribe and you will be taken off the list.

I also have a stockbroking business to run during the day so anyone that does send me queries or ideas I will try and get back to you as soon as possible.

**If you would like to be offered stock in the wide variety of placements and IPOs that I am showed please let me know and I will add you to my list so you have a chance to bid for the stock when it becomes available.**

**708 or sophisticated investors happy to show placements.**

**Non 708 investors happy to show any deals that are available for you to participate in.**

My company and I may receive fees from some companies mentioned in this report.

If you are receiving this from someone else please just send me an email directly and would be happy to add you to my distribution list.

And to finish off one of the world's longest disclaimers

Go Hard